CVSI - CV Sciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
1.2300
-0.0500 (-3.91%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close1.2800
Open1.2400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.1800 - 1.2600
52 Week Range1.1800 - 6.5900
Volume1,044,951
Avg. Volume843,006
Market Cap122.136M
Beta (3Y Monthly)1.81
PE Ratio (TTM)N/A
EPS (TTM)-0.0730
Earnings DateNov 5, 2019 - Nov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.80
  • GlobeNewswire

    CV Sciences, Inc. Announces New Distribution Partnership With Southeastern Grocers

    New Partnership with Southeastern Grocers Launches PlusCBD™ Oil Topical Products and Dietary Supplements at 115 Winn-Dixie Stores in Florida and 37 BI-LO Stores in South.

  • CV Sciences, Inc. (CVSI) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    CV Sciences, Inc. (CVSI) Reports Q3 Loss, Misses Revenue Estimates

    CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of -300.00% and -32.29%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    CV Sciences, Inc. Reports Third Quarter 2019 Financial Results

    Increased Retail Distribution by Over 800 Stores SAN DIEGO, Nov. 05, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent.

  • GlobeNewswire

    CV Sciences, Inc. Applauds USDA’s Establishment of the U.S. Domestic Hemp Production Program

    CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, is pleased to announce its support of the U.S. Department of Agriculture’s (USDA) progress on implementation of the hemp provisions of the 2018 Farm Bill. On October 29, 2019, U.S. Secretary of Agriculture Sonny Perdue announced the interim final rule for the U.S. Domestic Hemp Production Program.

  • Analysts Estimate CV Sciences, Inc. (CVSI) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate CV Sciences, Inc. (CVSI) to Report a Decline in Earnings: What to Look Out for

    CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    CV Sciences, Inc. Appoints Beth Altman to its Board of Directors

    SAN DIEGO, Oct. 29, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD).

  • GlobeNewswire

    CV Sciences, Inc. to Sponsor 26th Annual HIACON Conference in Charlotte, North Carolina on Nov. 1-4, 2019

    This year’s conference will be held November 1st through November 4th in Charlotte, North Carolina, and marks a significant milestone for HIACON as the longest-standing hemp conference in its 26th year. “We are looking forward to joining HIACON as the title sponsor for our 4th consecutive year,” said Joseph Dowling, Chief Executive Officer of CV Sciences.

  • GlobeNewswire

    CV Sciences, Inc. to Announce Third Quarter 2019 Results on November 5, 2019

    SAN DIEGO, Oct. 23, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD).

  • GlobeNewswire

    CV Sciences, Inc. Appoints Dr. Paul Blake to its Board of Directors

    CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced the appointment of Dr. Paul Blake to its Board of Directors effective October 21, 2019. “We are very pleased to have Dr. Blake join our Board of Directors,” said Joseph Dowling, Chief Executive Officer of CV Sciences.

  • GlobeNewswire

    CV Sciences, Inc. Announces Expanded Distribution Partnership With The Vitamin Shoppe

    Partnership Broadens Distribution of PlusCBD™ Oil Products to More Than 500 The Vitamin Shoppe Locations SAN DIEGO, Oct. 17, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the.

  • GlobeNewswire

    CV Sciences, Inc. Announces Distribution Partnership With Harris Teeter

    Partnership Broadens Distribution of PlusCBD™ Oil Products to 150 Harris Teeter Locations SAN DIEGO, Oct. 01, 2019 --  CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV.

  • GlobeNewswire

    CV Sciences Applauds House Passage of the SAFE Banking Act of 2019

    CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, announces its full support of the House of Representatives’ passage of the Secure and Fair Enforcement (SAFE) Banking Act, a key measure that would enable banks to serve cannabis-related businesses in legal medical and adult-use U.S. states. The SAFE Banking Act passed the House on Wednesday, September 25th by a vote of 321 to 103, becoming the first standalone marijuana reform bill to ever clear a chamber of Congress. “This is a significant step for the evolution and advancement of the legal cannabis industry,” said Joseph Dowling, Chief Executive Officer of CV Sciences.

  • GlobeNewswire

    CV Sciences, Inc. Launches Seven New Body Care Hemp CBD Products at Natural Products Expo East

    SAN DIEGO, Sept. 24, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol.

  • GlobeNewswire

    CV Sciences, Inc. Announces Plans to File Request For Continued Examination of Its US Patent Application

    SAN DIEGO, Sept. 19, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol.

  • GlobeNewswire

    CV Sciences, Inc. Wins 2019 NEXTY Award

    Company’s industry-dominating hemp extract brand, PlusCBD Oil™, wins Consumer Choice Award at Natural Products Expo East SAN DIEGO, Sept. 17, 2019 -- CV Sciences, Inc..

  • GlobeNewswire

    Pro Mountain Biker Cam McCaul Partners with PlusCBD™ Oil

    CV Sciences, Inc. (CVSI) (the “Company,” “CV Sciences,” “our” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, is pleased to announce they have partnered with professional mountain biker Cam McCaul to endorse industry-dominating PlusCBD™ Oil brand. McCaul, one of the leading riders on the freeride mountain biking scene for the past two decades, has won major global freeride events, including Crankworx Colorado, the Bearclaw Invitational, District Ride, and the Claymore Challenge. McCaul was an early leader in the sport of mountain bike slopestyle and has helped innovate both the sport and the riding style.

  • GlobeNewswire

    CV Sciences, Inc. to Present and Sponsor Natural Products Expo East

    Company enters its 5th year exhibiting at the nation's largest natural products trade show, offering natural health retailers show specials, one-on-one education, and a wide.

  • GlobeNewswire

    CV Sciences, Inc Appoints Terri Funk Graham to Board of Directors

    CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that Terri Funk Graham has been appointed to CV Sciences’ Board of Directors effective August 22, 2019. “Terri brings extensive Fortune 1000 experience serving on Boards of Directors and in senior leadership roles – we are thrilled to welcome her to our Board of Directors,” said Joseph Dowling, Chief Executive Officer of CV Sciences.

  • GlobeNewswire

    CV Sciences, Inc. Announces Distribution Partnership With The Vitamin Shoppe

    Partnership Broadens Distribution of PlusCBD™ Oil Products to More Than 380 Vitamin Shoppe Locations SAN DIEGO, Aug. 22, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”,.

  • Better CBD Stock: Charlotte's Web vs. CV Sciences
    Motley Fool

    Better CBD Stock: Charlotte's Web vs. CV Sciences

    Which purveyor of high-margin, nonintoxicating cannabis products will earn the largest share of this growing market?

  • GlobeNewswire

    CV Sciences, Inc. CEO Issues Letter to Shareholders

    CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products through its industry-dominating brand, PlusCBD™ Oil, today released a letter to shareholders from CEO Joseph Dowling. Last week we issued our second quarter results, reporting the highest quarterly revenue in our company’s history, continuing a streak of 14 consecutive quarters of sequential revenue growth. This consistent growth is a reflection of the strength of the PlusCBD™ Oil brand and our growing distribution across retail channels.

  • Motley Fool

    Here's What You'll Want to Know About CV Sciences' Q2 Results

    CBD product sales continued to soar in the second quarter, but not as much as analysts expected.

  • CV Sciences, Inc. (CVSI) Meets Q2 Earnings Estimates
    Zacks

    CV Sciences, Inc. (CVSI) Meets Q2 Earnings Estimates

    CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 0.00% and -3.44%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    CV Sciences, Inc. Reports Second Quarter 2019 Financial Results

    Record quarterly revenue Increased retail distribution by over 1,200 stores SAN DIEGO, Aug. 06, 2019 -- CV Sciences, Inc. (OTCQB:CVSI) ("CV Sciences" or the “Company”).

  • Why the leading CBD oil maker CV Sciences just won a new overweight rating: CEO
    Yahoo Finance Video

    Why the leading CBD oil maker CV Sciences just won a new overweight rating: CEO

    Piper Jaffray initiates CV Sciences with an overweight rating and a price target that reflects an upside of more than 60%. CV Sciences CEO Joe Dowling joins Yahoo Finance's Zack Guzman and Sibile Marcellus, along with Carleton English, New York Post Hedge Fund Reporter, to discuss.